The global CRISPR-based gene editing market size was estimated to be USD 4.14 billion in 2023 and is expected to reach USD 18.84 billion by 2034 with a CAGR of 14.76% during the forecast period 2024-2034. Continuous advancements in CRISPR technology, rising demand for gene therapy, more funding and investment, rising prevalence of genetic disorders, and a growing emphasis on personalized medicine will all fuel market expansion.
The expanding range of applications in agriculture, healthcare, and industrial biotechnology is driving market growth for CRISPR technology. Ongoing advancements in CRISPR continue to enhance its efficiency, precision, and versatility. A study published by the National Library of Medicine in April 2023 highlights successful applications of CRISPR in clinical trials, with notable companies such as Editas Medicine and CRISPR Therapeutics reporting promising outcomes in gene therapies for conditions like Leber congenital amaurosis and beta-thalassemia.
By product and services, the CRISPR libraries segment accounted for the highest revenue-grossing segment in the global CRISPR-based gene editing market in 2023 owing to the growing demand for high-throughput screening and the need for comprehensive genetic analysis in research and therapeutic applications. For instance, in May 2023, Vertex Pharmaceuticals Incorporated and CRISPR Therapeutics announced a new non-exclusive licensing deal. This collaboration focuses on using CRISPR Therapeutics' CRISPR/Cas9 gene editing technology to accelerate the development of Vertex's hypoimmune cell treatments for type 1 diabetes, demonstrating CRISPR's practical applications and transformative potential in treating chronic illnesses. Additionally, the services segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing reliance on outsourced gene editing services, rising demand for custom CRISPR libraries, and the need for specialized expertise in experimental design and data analysis in various research and therapeutic applications.
By application, the biomedical research segment accounted for the highest revenue-grossing segment in the global CRISPR-based gene editing market in 2023 and is predicted to grow at the fastest CAGR during the forecast period owing to the increasing prevalence of genetic disorders, advancements in gene therapies, and heightened investment in biomedical research and development. For instance, in November 2023, the United Kingdom's Medicines and Healthcare Products Regulatory Agency (MHRA) approved CASGEVY, a ground-breaking treatment for sickle cell disease and transfusion-dependent beta thalassemia. This approval is an important milestone in the fight against these debilitating genetic illnesses, bringing new hope to patients who experience severe health issues and a decreased quality of life.
By end-user, the pharmaceutical & biotechnology companies segment accounted for the highest revenue-grossing segment in the global CRISPR-based gene editing market in 2023 owing to the growing investments in research and development, the rising demand for innovative therapies, and the growing focus on personalized medicine. For instance, in February 2023, Vertex hinted to the launch strategy for the first CRISPR gene editing medicine, which is still awaiting FDA approval. The medication, developed in collaboration with CRISPR Therapeutics, is aimed at a specific population of patients with severe disease, estimated to number roughly 32,000 people in the United States and Europe. These individuals are clustered in specific geographic regions and usually undergo recurrent vaso-occlusive crises or rely on regular blood transfusions, needing multiple hospitalizations annually. Additionally, the contract research organizations segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing demand for outsourced research services, the need for specialized expertise in gene editing, and the growing number of partnerships between academic institutions and industry.
North American region is anticipated for the highest revenue share during the forecast period owing to the presence of leading biotechnology and pharmaceutical companies, significant investment in research and development, and a favorable regulatory environment for gene editing technologies. Additionally, the Asia Pacific region is predicted to grow at the fastest CAGR during the forecast period owing to increasing investments in biotechnology, a rising number of research initiatives, and a growing demand for innovative therapies in emerging markets. For instance, in October 2023, the National Institutes of Health (NIH) awarded Yale School of Medicine a major grant of roughly USD 40 million. This grant will help to develop a gene-editing technology focused at targeting the human brain, advancing CRISPR-based gene therapy for neurological disorders.
This comprehensive research report focuses on the global and regional market size and forecasts from 2023 to 2034.
The expanding range of applications in agriculture, healthcare, and industrial biotechnology is driving market growth for CRISPR technology. Ongoing advancements in CRISPR continue to enhance its efficiency, precision, and versatility. A study published by the National Library of Medicine in April 2023 highlights successful applications of CRISPR in clinical trials, with notable companies such as Editas Medicine and CRISPR Therapeutics reporting promising outcomes in gene therapies for conditions like Leber congenital amaurosis and beta-thalassemia.
By product and services, the CRISPR libraries segment accounted for the highest revenue-grossing segment in the global CRISPR-based gene editing market in 2023 owing to the growing demand for high-throughput screening and the need for comprehensive genetic analysis in research and therapeutic applications. For instance, in May 2023, Vertex Pharmaceuticals Incorporated and CRISPR Therapeutics announced a new non-exclusive licensing deal. This collaboration focuses on using CRISPR Therapeutics' CRISPR/Cas9 gene editing technology to accelerate the development of Vertex's hypoimmune cell treatments for type 1 diabetes, demonstrating CRISPR's practical applications and transformative potential in treating chronic illnesses. Additionally, the services segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing reliance on outsourced gene editing services, rising demand for custom CRISPR libraries, and the need for specialized expertise in experimental design and data analysis in various research and therapeutic applications.
By application, the biomedical research segment accounted for the highest revenue-grossing segment in the global CRISPR-based gene editing market in 2023 and is predicted to grow at the fastest CAGR during the forecast period owing to the increasing prevalence of genetic disorders, advancements in gene therapies, and heightened investment in biomedical research and development. For instance, in November 2023, the United Kingdom's Medicines and Healthcare Products Regulatory Agency (MHRA) approved CASGEVY, a ground-breaking treatment for sickle cell disease and transfusion-dependent beta thalassemia. This approval is an important milestone in the fight against these debilitating genetic illnesses, bringing new hope to patients who experience severe health issues and a decreased quality of life.
By end-user, the pharmaceutical & biotechnology companies segment accounted for the highest revenue-grossing segment in the global CRISPR-based gene editing market in 2023 owing to the growing investments in research and development, the rising demand for innovative therapies, and the growing focus on personalized medicine. For instance, in February 2023, Vertex hinted to the launch strategy for the first CRISPR gene editing medicine, which is still awaiting FDA approval. The medication, developed in collaboration with CRISPR Therapeutics, is aimed at a specific population of patients with severe disease, estimated to number roughly 32,000 people in the United States and Europe. These individuals are clustered in specific geographic regions and usually undergo recurrent vaso-occlusive crises or rely on regular blood transfusions, needing multiple hospitalizations annually. Additionally, the contract research organizations segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing demand for outsourced research services, the need for specialized expertise in gene editing, and the growing number of partnerships between academic institutions and industry.
North American region is anticipated for the highest revenue share during the forecast period owing to the presence of leading biotechnology and pharmaceutical companies, significant investment in research and development, and a favorable regulatory environment for gene editing technologies. Additionally, the Asia Pacific region is predicted to grow at the fastest CAGR during the forecast period owing to increasing investments in biotechnology, a rising number of research initiatives, and a growing demand for innovative therapies in emerging markets. For instance, in October 2023, the National Institutes of Health (NIH) awarded Yale School of Medicine a major grant of roughly USD 40 million. This grant will help to develop a gene-editing technology focused at targeting the human brain, advancing CRISPR-based gene therapy for neurological disorders.
This comprehensive research report focuses on the global and regional market size and forecasts from 2023 to 2034.
Report Scope:
- Base Year: 2023
- Forecast Period: 2024-2034
- Study Coverage
- Market Forecast by Product and Services, Application, and End-User
- Market Forecast for 5 Regions and 17+ Countries
- North America (U.S. and Canada)
- Europe (Germany, France, UK, Spain, Italy, Russia, Rest of Europe)
- Asia Pacific (China, Japan, India, Australia, South Korea, Rest of APAC)
- Latin America (Brazil, Mexico, Argentina, Rest of LATAM)
- MEA (South Africa, GCC, Rest of MEA)
- Exhaustive Company Profiles of the Top 10+ Major Market Players
- 20% Free Customization Available to Meet Your Exact Requirement.
Segmentation: CRISPR-based Gene Editing Market Report 2023 - 2034
CRISPR-based Gene Editing Market Analysis & Forecast by Product and Services 2023 - 2034 (Revenue USD Bn)
- CRISPR Kits & Reagents
- CRISPR Libraries
- Others
- Services
CRISPR-based Gene Editing Market Analysis & Forecast by Application 2023 - 2034 (Revenue USD Bn)
- Biomedical Research
- Therapeutic Applications
- Agriculture
- Animal Biotechnology
- Industrial Biotechnology
CRISPR-based Gene Editing Market Analysis & Forecast by End-User 2023 - 2034 (Revenue USD Bn)
- Companies Contract Research Organizations
- Academic & Research Institutes
- Pharmaceutical & Biotechnology Companies
CRISPR-based Gene Editing Market Analysis & Forecast by Region 2023 - 2034 (Revenue USD Bn)
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- UK
- Spain
- Italy
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of APAC
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of LATAM
- Middle East & Africa
- South Africa
- GCC
- Rest of MEA
Table of Contents
1. Research Methodology
2. Introduction
4. Market Environment Analysis
5. Market Dynamics
7. CRISPR-based Gene Editing Market: Product and Services Estimates & Trend Analysis
8. CRISPR-based Gene Editing Market: Application Estimates & Trend Analysis
9. CRISPR-based Gene Editing Market: End-User Estimates & Trend Analysis
10. Regional Market Analysis
11. North America CRISPR-based Gene Editing Market
12. Europe Global CRISPR-based Gene Editing Market
13. Asia Pacific Global CRISPR-based Gene Editing Market
14. Latin America Global CRISPR-based Gene Editing Market
15. MEA Global CRISPR-based Gene Editing Market
16. Competitor Analysis
17. Company Profiles
Companies Mentioned
- CRISPR Therapeutics
- Editas Medicine
- Intellia Therapeutics
- Caribou Biosciences
- Cellectis
- Regeneron Pharmaceuticals
- Beam Therapeutics
- Synthego
- Ginkgo Bioworks
- Inscripta
- Egenesis
- Zymergen
- Acuitas Therapeutics
- Genomatica
- Thermo Fisher Scientific.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 200 |
| Published | December 2024 |
| Forecast Period | 2023 - 2034 |
| Estimated Market Value ( USD | $ 4.14 Billion |
| Forecasted Market Value ( USD | $ 18.84 Billion |
| Compound Annual Growth Rate | 14.7% |
| Regions Covered | Global |
| No. of Companies Mentioned | 15 |
